ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options
Jean‐Jacques Kiladjian(Délégation Paris 5), Christoph Klade(Intercell (Austria)), Francisca Ferrer‐Marín(Centre for Biomedical Network Research on Rare Diseases), Vasiliki Pappa(Children's Hospital of Philadelphia), Steffen Koschmieder(RWTH Aachen University), Martin Grießhammer(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie), Chloé James(Université de Bordeaux), Árpád Illés(University of Debrecen), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Kurt Krejcy(AOP Orphan (Austria)), Andreas Reiter(Heidelberg University), Stefanie Schlager(Hewlett-Packard (Austria)), Martin Unger, Eloise Beggiato, Tomasz Sacha, O Cerná, Valentín García‐Gutiérrez(Universidad de Alcalá), Evangelos Terpos(National and Kapodistrian University of Athens), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Haifa Kathrin Al‐Ali(University Hospital in Halle), Konstanze Döhner(University Hospital Ulm), Valerio De Stefano(Agostino Gemelli University Polyclinic), José Miguel Torregrosa Diaz(Hospital General Universitario Morales Meseguer), Maria Bieniaszewska(Gdańsk Medical University), Sebastian Grosicki(Medical University of Silesia), Joanna Góra‐Tybor, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Albert Woelfler(University of Graz), Victoria Empson(AOP Orphan (Austria)), Ciprian Tomuleasa(Iuliu Hațieganu University of Medicine and Pharmacy), Massimo Breccia(Policlinico Umberto I), Florian H. Heidel(Medizinische Hochschule Hannover), Stefan Schmidt(Innsbruck Medical University), Catalin Danaı̈la(Institutul Regional de Oncologie), Jiří Mayer(Central European Institute of Technology), Zsolt Nagy(Semmelweis University), Ana Manuela Crişan(Institutul Clinic Fundeni), Mihaela Lazaroiu, Alberto Álvarez‐Larrán(Hospital Clínic de Barcelona), Krauth Maria-Theresa(Medical University of Vienna), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 0
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k